Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06891443 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
A Phase 3 study of Eye Diseases and Retinal Disease, sponsored by Laboratoires Thea.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 14
- Study locations
NCT06891443 is a Phase 3 study of Eye Diseases and Retinal Disease that is actively recruiting participants, run by Laboratoires Thea. The registered enrollment target is 32 participants, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 14 study locations across 8 states.
The verdict
NCT06891443, a Phase 3 study of Eye Diseases and Retinal Disease, is actively recruiting participants, sponsored by Laboratoires Thea.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.
Conditions Studied
Interventions
- DRUG sepofarsen
- OTHER Placebo IVT
Study Locations (14)
Other
- Universitair Ziekenhuis Gent (UZ) - Ghent
- Centre de maladies rares CHNO des Quinze Vingt - Paris
- Justus-Liebig Universität - Department of Ophthalmology - Giessen
- Klinikum der Ludwig-Maximilian Universität München - München
- University of Tuebingen - Inst. for Ophthalmic Research - Tübingen
- Radboud Universitair Medisch Centrum - Nijmegen
- Moorfields Eye Hospital NHS Foundation Trust - London
California
- UCSF Wayne and Gladys Valley Center for Vision - San Francisco
Florida
- University of Miami - Bascom Palmer Eye Institute - Miami
Iowa
- University of Iowa - Iowa City
Minnesota
- University of Minnesota Medical School - Minneapolis
Pennsylvania
- University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics - Philadelphia
Alberta
- University of Alberta - Edmonton
Ontario
- The Hospital for Sick Children - SickKids - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06891443
The ClinicalTrials.gov registry entry for NCT06891443 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Laboratoires Thea, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Eye Diseases appearing as the primary indexed condition, and to 2 interventions - of which sepofarsen is the first listed.
NCT06891443 reports 14 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06891443 about?
NCT06891443 is a clinical study titled "Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)". The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.
What is the current status of trial NCT06891443?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2025-06-04. Estimated completion is 2028-10.
What conditions does trial NCT06891443 study?
This clinical trial studies the following conditions: Eye Diseases, Retinal Disease, Eye Diseases, Hereditary, Blindness, Sensation Disorders.
What interventions are being tested in trial NCT06891443?
The interventions under investigation include: sepofarsen (DRUG), Placebo IVT (OTHER).
Who is sponsoring clinical trial NCT06891443?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06891443 being conducted?
This trial has 14 study locations across California, Florida, Iowa, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
COMPLETED · Phase 3
-
Adaptive Optics Retinal Imaging
RECRUITING
-
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.